Source - SMW
AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation of benralizumab.

The opinion was formed around benralizumab being used as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting b-agonists.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said:

"This positive recommendation is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients with an eosinophilic phenotype. Benralizumab has the potential to make a real difference to patients with its combination of efficacy, speed of onset, convenience and the ability to reduce oral steroid use."




At 1:06pm: (LON:AZN) AstraZeneca PLC share price was -97.5p at 4864.5p



Related Charts

AstraZeneca (AZN)

-3.00p (-0.06%)
delayed 15:12PM